2026 Set to Be a Pivotal Year for Obesity Medications
TL;DR Summary
By 2026, two new oral obesity pills from Novo Nordisk and Eli Lilly are expected to hit the U.S. market, offering a more convenient alternative to injections and potentially capturing a significant share of the growing weight loss drug market, with prices expected to be lower than current injectable options.
- Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly CNBC
- Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management Yahoo Finance
- A new generation of weight-loss drugs is getting closer to patients. Here’s how they differ from Wegovy and Zepbound. MarketWatch
- Novo's oral semaglutide edges out CagriSema, Lilly's orforglipron as PCPs' most-anticipated obesity med Fierce Pharma
- Wegovy Maker Novo Nordisk Files For FDA Approval of Obesity Drug CagriSema The Wall Street Journal
Reading Insights
Total Reads
0
Unique Readers
3
Time Saved
4 min
vs 5 min read
Condensed
94%
815 → 50 words
Want the full story? Read the original article
Read on CNBC